Top

Published in:

01-01-2015 | Gastrointestinal Oncology

Clinical Significance of Surgical Resection for the Recurrence of Esophageal Cancer After Radical Esophagectomy

Authors: Yukiharu Hiyoshi, MD, PhD, Masaru Morita, MD, PhD, FACS, Hiroyuki Kawano, MD, Hajime Otsu, MD, Koji Ando, MD, PhD, Shuhei Ito, MD, PhD, Yuji Miyamoto, MD, PhD, Yasuo Sakamoto, MD, PhD, Hiroshi Saeki, MD, PhD, Eiji Oki, MD, PhD, Tetsuo Ikeda, MD, PhD, Hideo Baba, MD, PhD, FACS, Yoshihiko Maehara, MD, PhD, FACS

Published in: Annals of Surgical Oncology | Issue 1/2015

Abstract

Background

This study aimed to clarify the clinical significance of surgical resection for recurrent lesions after esophagectomy for esophageal cancer.

Methods

Recurrence was detected in 113 of 365 consecutive patients who underwent surgical resection for esophageal cancer, and some treatment was performed for recurrence in 100 of the 113 patients. The treatments were classified into two groups: chemotherapy and/or radiation with surgery (surgery group, n = 14) and chemotherapy and/or radiation without surgery (no surgery group, n = 86). The outcomes were retrospectively analyzed.

Results

Of the 14 patients in the surgery group, 3 underwent repeated resection. Thus, a total of 22 resections were performed for these patients. The resected organs were the lymph nodes in nine patients, the lungs in six patients, local recurrence in two patients, subcutaneous recurrence in two patients, the liver in one patient, the brain in one patient, and the parotid gland in one patient. Among the 22 recurrent cases, 20 involved solitary lesions or multiple lesions located in a small resectable region. When the two groups were compared, the surgery group showed a more favorable prognosis in terms of both survival after esophagectomy (median survival time, 103.3 vs 23.1 months; p = 0.0060) and survival after initial recurrence (92.1 vs 12.2 months; p = 0.0057).

Conclusions

Multimodal treatment provides a significant benefit for patients with recurrence after esophagectomy for esophageal cancer. Surgical intervention should be aggressively included in the treatment strategy when the recurrent lesion is solitary or localized.

Akiyama H, Tsurumaru M, Kawamura T, Ono Y. Principles of surgical treatment for carcinoma of the esophagus: analysis of lymph node involvement. Ann Surg. 1981;194:438–46.PubMedCentralPubMedCrossRef

Matthews HR, Powell DJ, McConkey CC. Effect of surgical experience on the results of resection for oesophageal carcinoma. Br J Surg. 1986;73:621–3.PubMedCrossRef

Skinner DB, Little AG, Ferguson MK, Soriano A, Staszak VM. Selection of operation for esophageal cancer based on staging. Ann Surg. 1986;204:391–401.PubMedCentralPubMedCrossRef

Dresner SM, Griffin SM. Pattern of recurrence following radical oesophagectomy with two-field lymphadenectomy. Br J Surg. 2000;87:1426–33.PubMedCrossRef

Hulscher JB, van Sandick JW, Tijssen JG, Obertop H, van Lanschot JJ. The recurrence pattern of esophageal carcinoma after transhiatal resection. J Am Coll Surg. 2000;191:143–8.PubMedCrossRef

Nakagawa S, Kanda T, Kosugi S, Ohashi M, Suzuki T, Hatakeyama K. Recurrence pattern of squamous cell carcinoma of the thoracic esophagus after extended radical esophagectomy with three-field lymphadenectomy. J Am Coll Surg. 2004;198:205–11.PubMedCrossRef

Morita M, Yoshida R, Ikeda K, et al. Advances in esophageal cancer surgery in Japan: an analysis of 1,000 consecutive patients treated at a single institute. Surgery. 2008;143:499–508.PubMedCrossRef

Morita M, Kuwano H, Ohno S, Furusawa M, Sugimachi K. Characteristics and sequence of the recurrent patterns after curative esophagectomy for squamous cell carcinoma. Surgery. 1994;116:1–7.PubMed

Sugiyama M, Morita M, Yoshida R, et al. Patterns and time of recurrence after complete resection of esophageal cancer. Surg Today. 2012;42:752–8.PubMedCrossRef

10.

Motoyama S, Kitamura M, Saito R, Maruyama K, Okuyama M, Ogawa J. Outcome and treatment strategy for mid- and lower-thoracic esophageal cancer recurring locally in the lymph nodes of the neck. World J Surg. 2006;30:191–8.PubMedCrossRef

11.

Yano M, Takachi K, Doki Y, et al. Prognosis of patients who develop cervical lymph node recurrence following curative resection for thoracic esophageal cancer. Dis Esophagus. 2006;19:73–7.PubMedCrossRef

12.

Nakamura T, Ota M, Narumiya K, et al. Multimodal treatment for lymph node recurrence of esophageal carcinoma after curative resection. Ann Surg Oncol. 2008;15:2451–7.PubMedCrossRef

13.

Ichikawa H, Kosugi S, Nakagawa S, et al. Operative treatment for metachronous pulmonary metastasis from esophageal carcinoma. Surgery. 2011;149:164–70.PubMedCrossRef

14.

Takemura M, Sakurai K, Takii M, Yoshida K. Metachronous pulmonary metastasis after radical esophagectomy for esophageal cancer: prognosis and outcome. J Cardiothorac Surg. 2012;7:103.PubMedCentralPubMedCrossRef

15.

Chen F, Sato K, Sakai H, et al. Pulmonary resection for metastasis from esophageal carcinoma. Interact Cardiovasc Thorac Surg. 2008;7:809–12.PubMedCrossRef

16.

Hironaka S, Ohtsu A, Boku N, et al. Nonrandomized comparison between definitive chemoradiotherapy and radical surgery in patients with T(2-3)N(any) M(0) squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys. 2003;57:425–33.PubMedCrossRef

17.

Law S, Kwong DL, Kwok KF, et al. Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg. 2003;238:339–47; discussion 347–338.PubMedCentralPubMed

18.

Shimada H, Kitabayashi H, Nabeya Y, et al. Treatment response and prognosis of patients after recurrence of esophageal cancer. Surgery. 2003;133:24–31.PubMedCrossRef

19.

Chen G, Wang Z, Liu XY, Liu FY. Recurrence pattern of squamous cell carcinoma in the middle thoracic esophagus after modified Ivor-Lewis esophagectomy. World J Surg. 2007;31:1107–14.PubMed

20.

Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84:324–38.PubMedCrossRef

21.

Oki E, Morita M, Kakeji Y, et al. Salvage esophagectomy after definitive chemoradiotherapy for esophageal cancer. Dis Esophagus. 2007;20:301–4.PubMedCrossRef

22.

Swisher SG, Wynn P, Putnam JB, et al. Salvage esophagectomy for recurrent tumors after definitive chemotherapy and radiotherapy. J Thorac Cardiovasc Surg. 2002;123:175–83.PubMedCrossRef

23.

Morita M, Kumashiro R, Hisamatsu Y, et al. Clinical significance of salvage esophagectomy for remnant or recurrent cancer following definitive chemoradiotherapy. J Gastroentero. 2011;46:1284–91.CrossRef

24.

Kadota H, Fukushima J, Nakashima T, et al. Comparison of salvage and planned pharyngolaryngectomy with jejunal transfer for hypopharyngeal carcinoma after chemoradiotherapy. Laryngoscope. 2010;120:1103–8.PubMed

25.

Ida S, Morita M, Hiyoshi Y, et al. Surgical resection of hypopharynx and cervical esophageal cancer with a history of esophagectomy for thoracic esophageal cancer. Ann Surg Oncol. 2014;21:1175–81.

26.

Uchiyama H, Shirabe K, Morita M, et al. Expanding the applications of microvascular surgical techniques to digestive surgeries: a technical review. Surg Today. 2012;42:111–20.PubMedCrossRef

27.

Kato H, Nakajima M. The efficacy of FDG-PET for the management of esophageal cancer: review article. Ann Thorac Cardiovasc Surg. 2012;18:412–9.PubMedCrossRef

28.

Hayashi K, Ando N, Watanabe H, et al. Phase II evaluation of protracted infusion of cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG) Trial (JCOG9407). Jpn J Clin Oncol. 2001;31:419–23.PubMedCrossRef

29.

Bleiberg H, Conroy T, Paillot B, et al. Randomised phase II study of cisplatin and 5-fluorouracil (5-FU) versus cisplatin alone in advanced squamous cell oesophageal cancer. Eur J Cancer Oxford Eng 1997;33:1216–20.CrossRef

30.

Muro K, Hamaguchi T, Ohtsu A, et al. A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol. 2004;15:955–9.PubMedCrossRef

31.

Ilson DH, Ajani J, Bhalla K, et al. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus. J Clin Oncol. 1998;16:1826–34.PubMed

32.

Yamasaki M, Miyata H, Tanaka K, et al. Multicenter phase I/II study of docetaxel, cisplatin, and fluorouracil combination chemotherapy in patients with advanced or recurrent squamous cell carcinoma of the esophagus. Oncology. 2011;80:307–13.PubMedCrossRef

Title: Clinical Significance of Surgical Resection for the Recurrence of Esophageal Cancer After Radical Esophagectomy
Authors: Yukiharu Hiyoshi, MD, PhD
Masaru Morita, MD, PhD, FACS
Hiroyuki Kawano, MD
Hajime Otsu, MD
Koji Ando, MD, PhD
Shuhei Ito, MD, PhD
Yuji Miyamoto, MD, PhD
Yasuo Sakamoto, MD, PhD
Hiroshi Saeki, MD, PhD
Eiji Oki, MD, PhD
Tetsuo Ikeda, MD, PhD
Hideo Baba, MD, PhD, FACS
Yoshihiko Maehara, MD, PhD, FACS
Publication date: 01-01-2015
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 1/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3970-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Clinical Significance of Surgical Resection for the Recurrence of Esophageal Cancer After Radical Esophagectomy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

A Modified Intracorporeal Billroth-I Anastomosis After Laparoscopic Distal Gastrectomy for Gastric Cancer: A Safe and Feasible Technique

Breast Conservation in the Setting of Contemporary Multimodality Treatment Provides Excellent Outcomes for Patients with Occult Primary Breast Cancer

Management of Primary Retroperitoneal Sarcoma (RPS) in the Adult: A Consensus Approach From the Trans-Atlantic RPS Working Group

Cumulative Prognostic Scores Based on Plasma Fibrinogen and Serum Albumin Levels in Esophageal Cancer Patients Treated with Transthoracic Esophagectomy: Comparison with the Glasgow Prognostic Score

A Multicenter Phase I Dose Escalation Trial to Evaluate Safety and Tolerability of Intra-arterial Temozolomide for Patients with Advanced Extremity Melanoma Using Normothermic Isolated Limb Infusion

Survival Outcomes of Metaplastic Breast Cancer Patients: Results from a US Population-based Analysis